Lenalidomide Treatment for lower risk non-deletion 5q Myelodysplastic syndromes Patients Yields higher Response Rates when Used Prior to Azanucleosides

Conclusions Lenalidomide appears to yield a higher HI-E rate in non-del5q LR-MDS when used as first-line therapy after ESAs failure. If validated in larger cohorts, lenalidomide rather than azacitidine should be considered for first-line therapy after ESAs failure. Teaser In patients with lower-risk myelodysplastic syndromes (LR-MDS) in whom erythropoiesis-stimulating agents (ESAs) fail, optimal sequencing of lenalidomide and azanucleosides is unknown. In a retrospective analysis of patients who received both azacitidine and lenalidomide, erythroid hematologic improvement rate was 38% vs. 12% when lenalidomide was used as first-line vs. second-line therapy (p=0.04). Use of lenalidomide before azacitidine should be considered after ESAs failure in LR-MDS.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research